Humanize murine antibody sequences using CDR grafting and framework optimization to reduce immunogenicity while preserving antigen binding. Predicts optimal human germline frameworks and identifies critical back-mutations for therapeutic antibody development.
Install with the open skills CLI (global, non-interactive — available in every Claude Code session):
npx skills add LeoYeAI/openclaw-master-skills --skill "antibody-humanizer" -g -a claude-code -yOr manually — clone and copy the skill directory (SKILL.md + companion files):
git clone --depth 1 https://github.com/LeoYeAI/openclaw-master-skills /tmp/openclaw-master-skills && cp -r /tmp/openclaw-master-skills/skills/antibody-humanizer ~/.claude/skills/antibody-humanizerThis skill is a directory: SKILL.md is the entry point; the files below ship with it.
---
name: antibody-humanizer
description: Humanize murine antibody sequences using CDR grafting and framework
optimization to reduce immunogenicity while preserving antigen binding. Predicts
optimal human germline frameworks and identifies critical back-mutations for
therapeutic antibody development.
allowed-tools: [Read, Write, Bash, Edit]
license: MIT
metadata:
skill-author: AIPOCH
---
# Antibody Humanizer
## Overview
Bioinformatics platform for converting murine antibodies into humanized variants by grafting complementarity-determining regions (CDRs) onto human framework templates while preserving antigen-binding affinity and reducing immunogenicity risk.
**Key Capabilities:**
- **CDR Identification**: Automatic CDR boundary detection (Kabat/Chothia/IMGT schemes)
- **Framework Matching**: Database search for optimal human germline templates
- **Humanization Scoring**: Multi-parameter immunogenicity risk assessment
- **Back-Mutation Prediction**: Identify critical framework residues for retention
- **Batch Processing**: Humanize multiple antibody candidates efficiently
- **Immunogenicity Assessment**: T-cell epitope and humanness scoring
## When to Use
**✅ Use this skill when:**
- Converting murine hybridoma antibodies to therapeutic candidates
- Reducing immunogenicity risk of rodent-derived antibodies
- Selecting human framework templates for CDR grafting
- Identifying critical framework residues for antigen binding
- Comparing multiple humanization strategies for lead optimization
- Preparing antibody sequences for patent filings
- Teaching antibody engineering principles
**❌ Do NOT use when:**
- Fully human antibody generation from phage display → Use `phage-display-library`
- De novo antibody design → Use `antibody-design-ai`
- Affinity maturation → Use `affinity-maturation-predictor`
- ADCC/CDC optimization → Use `fc-engineering-toolkit`
- Final therapeutic candidate selection → Requires experimental validation
**Integration:**
- **Upstream**: `antibody-sequencer` (VH/VL sequence determination), `cdr-grafting-validator` (structural assessment)
- **Downstream**: `protein-struct-viz` (3D visualization), `immunogenicity-predictor` (T-cell epitope analysis)
## Core Capabilities
### 1. CDR Region Identification
Parse antibody sequences and identify CDR boundaries:
```python
from scripts.humanizer import AntibodyHumanizer
humanizer = AntibodyHumanizer()
# Analyze antibody sequence
analysis = humanizer.analyze_sequence(
vh_sequence="QVQLQQSGPELVKPGASVKISCKASGYTFTDYYMHWVKQSHGKSLEWIGYINPSTGYTEYNQKFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYYCAR...",
vl_sequence="DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYPYT...",
scheme="chothia" # Options: kabat, chothia, imgt
)
# Output CDR locations
print(analysis.cdr_regions)
# {
# "VH_CDR1": {"start": 26, "end": 32, "seq": "GYTFTDY"},
# "VH_CDR2": {"start": 52, "end": 58, "seq": "INPSTGY"},
# ...
# }
```
**Numbering Schemes:**
| Scheme | VH CDR1 | VH CDR2 | VH CDR3 | Best For |
|--------|---------|---------|---------|----------|
| **Chothia** | 26-32 | 52-56 | 95-102 | Structural analysis |
| **Kabat** | 31-35 | 50-65 | 95-102 | Sequence-based work |
| **IMGT** | 27-38 | 56-65 | 105-117 | Standardized analysis |
### 2. Human Framework Matching
Identify optimal human germline templates:
```python
# Match against human germline database
matches = humanizer.find_human_frameworks(
vh_framework=analysis.vh_frameworks,
vl_framework=analysis.vl_frameworks,
top_n=5,
criteria=["homology", "canonical_structure", "vernier_similarity"]
)
# Evaluate each candidate
for match in matches:
print(f"Template: {match.germline_genes}")
print(f"Homology: {match.homology:.2%}")
print(f"Vernier Score: {match.vernier_score:.1f}")
print(f"Risk Level: {match.immunogenicity_risk}")
```
**Matching Criteria:**
- **Sequence Homology**: Percent identity to human germline
- **Canonical Structure**: Loop conformation compatibility
- **Vernier Region**: Framework residues contacting CDRs
- **Interface Residues**: Packing interactions with CDRs
### 3. Humanization Scoring
Assess immunogenicity risk of candidates:
```python
# Score humanization candidates
scores = humanizer.score_candidates(
murine_antibody=analysis,
human_templates=matches,
scoring_methods=["t20", "h_score", "germline_deviation", "paratope_diversity"]
)
# Rank by overall score
ranked = scores.rank_by_composite_score(
weights={"humanness": 0.4, "binding_retention": 0.4, "developability": 0.2}
)
```
**Scoring Methods:**
| Method | Description | Target |
|--------|-------------|--------|
| **T20 Score** | 20-mer peptide humanization | >80% human |
| **H-Score** | Hummerblind germline distance | <15 mutations |
| **Paratope Diversity** | CDR germline gene diversity | Low diversity |
| **Developability** | Aggregation/pH stability prediction | High score |
### 4. Back-Mutation Prediction
Identify critical residues to retain from murine framework:
```python
# Predict back-mutations
back_mutations = humanizer.predict_back_mutations(
murine_vh=analysis.vh_sequence,
human_vh=matches[0].human_template,
cdr_regions=analysis.cdr_regions,
rationale_required=True
)
# Output shows position-specific recommendations
for mutation in back_mutations:
print(f"Position {mutation.position}: {mutation.human_aa} → {mutation.murine_aa}")
print(f"Rationale: {mutation.reason}") # e.g., "Vernier region contact"
print(f"Priority: {mutation.priority}") # Critical/Important/Optional
```
**Critical Residue Classes:**
- **Vernier Positions**: Framework residues contacting CDRs (VH 24, 71, 94)
- **Interface Packs**: Residue packing between VH and VL
- **Canonical Anchors**: Cysteines and conserved framework positions
- ** Buried Positions**: Core packing residues affecting stability
## Common Patterns
### Pattern 1: Standard Therapeutic Humanization
**Scenario**: Convert murine anti-tumor antibody to therapeutic candidate.
```bash
# Humanize single antibody
python scripts/main.py \
--vh "QVQLQQSGPELVKPGASVKISCKAS..." \
--vl "DIQMTQSPSSLSASVGDRVTITCRAS..." \
--name "Anti-HER2-Murine-1" \
--scheme chothia \
--top-n 3 \
--output humanization_report.json
# Review top candidates
cat humanization_report.json | jq '.candidates[0]'
```
**Workflow:**
1. Input murine VH/VL sequences
2. Identify CDRs using Chothia scheme
3. Match to human germline database
4. Score top 3 candidates
5. Identify required back-mutations
6. Output humanized sequences
### Pattern 2: Batch Humanization Screening
**Scenario**: Screen multiple murine clones from hybridoma campaign.
```python
# Process multiple antibodies
antibodies = [
{"name": "Clone-A", "vh": "...", "vl": "..."},
{"name": "Clone-B", "vh": "...", "vl": "..."},
{"name": "Clone-C", "vh": "...", "vl": "..."}
]
results = humanizer.batch_humanize(
antibodies=antibodies,
ranking_criteria="composite_score",
min_humanness=0.85
)
# Rank by developability
ranked = results.rank_by(criteria=["humanness", "binding_retention", "stability"])
```
**Selection Criteria:**
- Highest humanness score (>85%)
- Fewest back-mutations required (<6)
- Low immunogenicity risk
- Good developability profile
### Pattern 3: Framework Template Comparison
**Scenario**: Compare different humanization strategies for lead candidate.
```python
# Test multiple framework combinations
strategies = [
{"vh": "IGHV1-2*02", "vl": "IGKV1-12*01", "name": "Template-A"},
{"vh": "IGHV3-23*01", "vl": "IGKV3-20*01", "name": "Template-B"},
{"vh": "IGHV4-34*01", "vl": "IGKV1-5*01", "name": "Template-C"}
]
comparison = humanizer.compare_strategies(
murine_antibody=analysis,
strategies=strategies,
metrics=["homology", "back_mutations", "immunogenicity", "paratope_structure"]
)
comparison.generate_report("framework_comparison.pdf")
```
**Comparison Metrics:**
- Sequence identity to human germline
- Number and location of back-mutations
- Predicted immunogenicity risk
- CDR conformation preservation
### Pattern 4: Intellectual Property Analysis
**Scenario**: Assess humanization for patent landscape analysis.
```bash
# Generate humanized variants
python scripts/main.py \
--input murine_lead.json \
--generate-variants 10 \
--include-back-mutations \
--output variants_for_ip.json
# Check novelty against patent databases
python scripts/patent_check.py \
--sequences variants_for_ip.json \
--databases [USPTO, EPO, WIPO] \
--output novelty_report.pdf
```
**IP Considerations:**
- Human framework combinations may be patented
- CDR sequences determine antigen specificity
- Back-mutation positions may be prior art
- Document humanization rationale for filings
## Complete Workflow Example
**From murine hybridoma to therapeutic candidate:**
```bash
# Step 1: Sequence analysis and CDR identification
python scripts/main.py \
--vh $VH_SEQUENCE \
--vl $VL_SEQUENCE \
--scheme chothia \
--output step1_analysis.json
# Step 2: Find best human frameworks
python scripts/main.py \
--input step1_analysis.json \
--find-frameworks \
--top-n 5 \
--output step2_frameworks.json
# Step 3: Score and rank candidates
python scripts/main.py \
--input step2_frameworks.json \
--score-candidates \
--include-immunogenicity \
--output step3_scored.json
# Step 4: Predict back-mutations
python scripts/main.py \
--input step3_scored.json \
--predict-back-mutations \
--rationale \
--output step4_backmutations.json
# Step 5: Generate final humanized sequences
python scripts/main.py \
--input step4_backmutations.json \
--generate-sequences \
--format fasta \
--output humanized_antibody.fasta
```
**Python API:**
```python
from scripts.humanizer import AntibodyHumanizer
from scripts.scoring import HumanizationScorer
from scripts.backmutation import BackMutationPredictor
# Initialize pipeline
humanizer = AntibodyHumanizer()
scorer = HumanizationScorer()
bm_predictor = BackMutationPredictor()
# Step 1: Parse and analyze
antibody = humanizer.analyze_sequence(
vh_sequence=murine_vh,
vl_sequence=murine_vl,
scheme="chothia"
)
# Step 2: Find human frameworks
candidates = humanizer.find_human_frameworks(
antibody,
top_n=5
)
# Step 3: Score candidates
for candidate in candidates:
scores = scorer.calculate_scores(
murine=antibody,
humanized=candidate
)
candidate.composite_score = scores.weighted_score()
# Step 4: Select best and predict back-mutations
best = max(candidates, key=lambda x: x.composite_score)
back_mutations = bm_predictor.predict(
murine=antibody,
human_template=best
)
# Step 5: Generate final sequence
final_sequence = humanizer.generate_humanized_sequence(
template=best,
back_mutations=back_mutations,
cdrs=antibody.cdr_regions
)
print(f"Humanized antibody generated:")
print(f"- Humanness: {best.humanness:.1%}")
print(f"- Back-mutations: {len(back_mutations)}")
print(f"- Risk level: {best.immunogenicity_risk}")
```
## Quality Checklist
**Input Quality:**
- [ ] VH and VL sequences complete (110-130 aa typical)
- [ ] No ambiguous residues (B, Z, X)
- [ ] Signal peptide removed
- [ ] Constant region removed (variable region only)
**Humanization Assessment:**
- [ ] CDR boundaries correctly identified
- [ ] Human framework homology >80%
- [ ] T20 score >75 (high humanness)
- [ ] Vernier positions analyzed for back-mutations
- [ ] Interface residues checked for packing
**Output Validation:**
- [ ] Humanized sequence valid (no stop codons)
- [ ] CDRs preserved exactly
- [ ] Framework length conserved
- [ ] Back-mutations documented with rationale
- [ ] **CRITICAL**: Immunogenicity risk assessed
**Before Experimental Work:**
- [ ] **CRITICAL**: Top 2-3 candidates selected for expression
- [ ] Binding affinity to be tested (ELISA/Biacore)
- [ ] Stability assessed (thermal/aggregation)
- [ ] Immunogenicity in vitro assays planned
## Common Pitfalls
**Sequence Issues:**
- ❌ **Incomplete sequences** → Missing framework regions
- ✅ Ensure full VH/VL variable domains provided
- ❌ **Wrong numbering scheme** → CDR boundaries incorrect
- ✅ Verify scheme matches experimental data source
- ❌ **Non-standard residues** → Unusual amino acids
- ✅ Clean sequences; remove signal peptides
**Design Issues:**
- ❌ **Over-humanization** → Losing antigen binding
- ✅ Don't exceed 85-90% humanness; retain critical residues
- ❌ **Ignoring back-mutations** → Assuming 100% human framework works
- ✅ Always predict and test back-mutations
- ❌ **Single candidate only** → No backup options
- ✅ Generate 2-3 candidates with different frameworks
**Experimental Issues:**
- ❌ **Skipping binding validation** → Assuming in silico = in vivo
- ✅ Always confirm antigen binding experimentally
- ❌ **Ignoring developability** → Aggregation or instability
- ✅ Check for problematic residues (unpaired cysteines, hydrophobic patches)
## References
Available in `references/` directory:
- `imgt_germline_database.md` - Human germline gene reference sequences
- `cdr_numbering_schemes.md` - Kabat, Chothia, IMGT comparison
- `humanization_case_studies.md` - Successful therapeutic examples
- `vernier_positions_guide.md` - Critical framework residues
- `immunogenicity_assessment.md` - T-cell epitope prediction methods
- `patent_landscape.md` - Humanization IP considerations
## Scripts
Located in `scripts/` directory:
- `main.py` - CLI interface for humanization
- `humanizer.py` - Core humanization engine
- `cdr_parser.py` - CDR identification and numbering
- `framework_matcher.py` - Human germline database search
- `scoring.py` - Humanization quality assessment
- `backmutation.py` - Critical residue prediction
- `batch_processor.py` - Multiple antibody screening
- `structure_predictor.py` - CDR conformation analysis
## Limitations
- **Binding Prediction**: Cannot accurately predict impact on antigen affinity
- **Developability**: Limited prediction of aggregation or stability issues
- **Immunogenicity**: In silico T-cell epitope prediction has false positives
- **Non-Standard Antibodies**: May not handle camelid, shark, or engineered scaffolds
- **Experimental Validation Required**: All predictions must be confirmed in vitro/vivo
- **Intellectual Property**: Does not check for existing patent claims on sequences
## Parameters
| Parameter | Type | Default | Required | Description |
|-----------|------|---------|----------|-------------|
| `--vh` | string | - | No | Murine VH sequence (amino acids) |
| `--vl` | string | - | No | Murine VL sequence (amino acids) |
| `--input`, `-i` | string | - | No | Input JSON file path |
| `--name`, `-n` | string | "" | No | Antibody name |
| `--output`, `-o` | string | - | No | Output file path |
| `--format`, `-f` | string | json | No | Output format (json, fasta, csv) |
| `--scheme`, `-s` | string | chothia | No | Numbering scheme (kabat, chothia, imgt) |
| `--top-n` | int | 3 | No | Number of best candidates to return |
## Usage
### Basic Usage
```bash
# Humanize with direct sequence input
python scripts/main.py --vh "QVQLQQSGPELVKPGASVKMSCKAS..." --vl "DIQMTQSPSSLSASVGDRVTITC..." --name "MyAntibody"
# Use JSON input file
python scripts/main.py --input antibody.json --output results.json
# Use IMGT numbering scheme
python scripts/main.py --vh "SEQUENCE" --vl "SEQUENCE" --scheme imgt
```
### Input JSON Format
```json
{
"vh_sequence": "QVQLQQSGPELVKPGASVKMSCKAS...",
"vl_sequence": "DIQMTQSPSSLSASVGDRVTITC...",
"name": "MyAntibody",
"scheme": "chothia"
}
```
## Risk Assessment
| Risk Indicator | Assessment | Level |
|----------------|------------|-------|
| Code Execution | Python script executed locally | Medium |
| Network Access | No external API calls | Low |
| File System Access | Read input files, write output files | Low |
| Instruction Tampering | Standard prompt guidelines | Low |
| Data Exposure | Output may contain proprietary sequences | Medium |
## Security Checklist
- [x] No hardcoded credentials or API keys
- [x] No unauthorized file system access (../)
- [x] Input validation for sequences
- [x] Prompt injection protections in place
- [x] Error messages sanitized
- [x] Output directory restricted to workspace
- [x] Script execution in sandboxed environment
## Prerequisites
```bash
# Python 3.7+
# No external packages required (uses standard library)
```
## Evaluation Criteria
### Success Metrics
- [x] Successfully parses antibody sequences
- [x] Identifies CDR regions correctly
- [x] Matches human germline frameworks
- [x] Predicts back-mutations
- [x] Generates valid humanized sequences
### Test Cases
1. **Basic Functionality**: Humanize valid VH/VL sequences → Returns candidates
2. **Edge Case**: Invalid sequence characters → Graceful error message
3. **File Input**: Process JSON input → Correctly parses and outputs
## Lifecycle Status
- **Current Stage**: Draft
- **Next Review Date**: 2026-03-06
- **Known Issues**: None
- **Planned Improvements**:
- Add T20 score database integration
- Support for camelid and shark antibodies
- Structure-based CDR prediction
---
**🔬 Critical Note: Computational humanization is a design tool, not a substitute for experimental validation. Always express and test humanized candidates for binding affinity, specificity, stability, and immunogenicity before therapeutic development.**
Search arXiv papers by keyword, author, category, or ID.
Gateway to 400+ bioinformatics skills from bioSkills and ClawBio. Covers genomics, transcriptomics, single-cell, variant calling, pharmacogenomics, metagenomics, structural biology, and more. Fetches domain-specific reference material on demand.
> Pharmaceutical research assistant for drug discovery workflows. Search bioactive compounds on ChEMBL, calculate drug-likeness (Lipinski Ro5, QED, TPSA, synthetic accessibility), look up drug-drug interactions via OpenFDA, interpret ADMET profiles, and assist with lead optimization. Use for medicinal chemistry questions, molecule property analysis, clinical pharmacology, and open-science drug research.